{
  "harness": "sj-harness 0.5.0",
  "job": "job:763e17a5789bdbf83808716862c001a3",
  "kind": "domain_review",
  "bundle": "sha256:858c5900a588f1b14f9c759333fa3e77d45402df97630bcfe3b8e566ca32db4c",
  "claims": [
    {
      "local_id": "C1",
      "claim_id": "claim:74ec34c98b1bc315a8cf51f75f158196c4071096e11bed3bea124637c0ffb577",
      "verdict": "minor_issues",
      "significance": "minor",
      "reason": "The claim holds as worded (its estimator re-implemented gives 1.167, 0.418 to 3.261), but it cites none of the meta-analyses that already pooled outpatient ivermectin trials (Cochrane 2022, Roman 2022, Marcolino 2022, Hill 2022), its purposive selection omits the double-blind IVERCOR-COVID19 trial with hospitalization as primary outcome (adding it moves the pooled RR to 1.00, 0.47 to 2.13), and the PRINCIPLE all-control figures were already in that trial's abstract."
    }
  ]
}